CN100417415C - Soakage of medication for treating arthritis - Google Patents
Soakage of medication for treating arthritis Download PDFInfo
- Publication number
- CN100417415C CN100417415C CNB2006100102301A CN200610010230A CN100417415C CN 100417415 C CN100417415 C CN 100417415C CN B2006100102301 A CNB2006100102301 A CN B2006100102301A CN 200610010230 A CN200610010230 A CN 200610010230A CN 100417415 C CN100417415 C CN 100417415C
- Authority
- CN
- China
- Prior art keywords
- medicine
- mixture
- energy
- units
- arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 206010003246 arthritis Diseases 0.000 title claims abstract description 11
- 229940079593 drug Drugs 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 24
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical group O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims abstract description 8
- 229930182566 Gentamicin Natural products 0.000 claims abstract description 8
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 8
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 8
- 229960004194 lidocaine Drugs 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 9
- 230000008595 infiltration Effects 0.000 claims description 6
- 238000001764 infiltration Methods 0.000 claims description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 4
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims description 4
- 229930010555 Inosine Natural products 0.000 claims description 4
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 4
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000005516 coenzyme A Substances 0.000 claims description 4
- 229940093530 coenzyme a Drugs 0.000 claims description 4
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims description 4
- 229960003786 inosine Drugs 0.000 claims description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 10
- 238000002347 injection Methods 0.000 abstract description 6
- 239000007924 injection Substances 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 210000003701 histiocyte Anatomy 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 abstract description 3
- 241001260012 Bursa Species 0.000 abstract description 2
- 230000001154 acute effect Effects 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 230000008878 coupling Effects 0.000 abstract description 2
- 238000010168 coupling process Methods 0.000 abstract description 2
- 238000005859 coupling reaction Methods 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 230000001976 improved effect Effects 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000007654 immersion Methods 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000019522 cellular metabolic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960002518 gentamicin Drugs 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000001171 synovial bursa Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 210000003131 sacroiliac joint Anatomy 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000167847 Koelreuteria paniculata Species 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides medicine for treating arthritis in an immersion mode, which is characterized in that the medicine is a mixture comprising 90 to 100 units of energy compound agent, 70 to 80 mg of compound bone peptide, 75, 000 to 80, 000 units of gentamicin and 5 to 6 mg of 2% lidocaine. The medicine of the present invention is used for treating the articular cavity and the bursa synovialis in an immersion and injection mode so that the medicine can directly reach affected histocyte and is combined with receptors for supplementing cell energy and activating the metabolism of cells. Therefore, the activity and the permeability of ectocellular enzymes are improved, acute and chronic non-specificity inflammatory reactions are resisted, damage of pathogenic factors to histiocyte is inhibited and prevented, and partial inflammatory reactions are eliminated. Finally, the medicine performs functions by means of energy coupling. Experiments in clinical application show that the medicine has the advantages of no side effect, reliable curative effect and high cure rate. The medicine has obvious curative effects on arthritis on the vertebral column and limbs.
Description
(1) technical field
What the present invention relates to is a kind of pharmaceutical composition, specifically a kind of pharmaceutical composition of treatment of arthritis.
(2) background technology
Arthritis is meant that the hypertrophic teoarthropathy, regression, periarticular soft tissues adhesion, the contracture that cause after long-term scorching change of periarticular soft tissues or the wound are a big class disease of main performance, be commonly encountered diseases, the frequently-occurring disease of each hospital outpatient, its prevalence height, disability rate are also very high.At present Chinese and western medicine has been carried out a large amount of research on this type of disease of treatment, but all seems on therapeutic effect and be pale and weak, and has caused patient's economic loss and body and mind misery, finally causes joint deformity.Chinese scholars belongs to the rheumatism category with this class disease at present, its cause of disease complexity, no matter be that infect, immunity, metabolic, endocrine and geographical environment etc., its pathological change is histiocyte inflammatory hyperemia, edema, oozes out and cell infiltration, finally causes joint hyperplasia, regression, soft tissue adhesion, contracture, the dysfunction of getting involved.
(3) summary of the invention
The object of the invention is to provide a kind of medicine that arthritis is had the infiltration treatment of arthritis of excellent curative.
The object of the present invention is achieved like this: it is the resulting mixture of mixed according to Energy mixture 90-100 unit, complex bone peptide 70-80mg, gentamycin 7.5-8 ten thousand units and 2% lignocaine 5-6mg, and described Energy mixture is adenosine triphosphate, coenzyme A and 1: 1: 1 mixture of inosine.
Energy mixture among the present invention is the coenzyme of histiocyte ethane reaction, participates in sugar in the body, fat, protein and nucleotide metabolism, becomes or the cellular enzymes all kinds of diseases that cause that go down in damage back have therapeutic effect histiocyte is scorching.The antiinflammatory action of gentamycin is strong, and is splendid to each bacteroid action effect, is difficult for producing drug resistance.But the pathological changes of complex bone peptide antagonism nonspecific inflammation is quickened partial blood circulation and metabolite and is removed, and improves weary oxygen of pathological tissues and metabolite and piles up the old goldenrain tree that causes.Lignocaine is a local anaesthetics, can stablize the cell membrane of nerve fiber, makes action potential can't conduct, make the neural sensation function to be blocked, to remove vasospasm, thereby interrupts lesion pain conduction vicious cycle, reaches therapeutic purposes.
The present invention mixes these compositions, row articular cavity and the treatment of synovial membrane capsule infiltration injecting, make medicine can directly reach the histiocyte of getting involved, and and receptors bind, cellular energy replenished, the metabolism of active cell, thereby improve the activity and the permeability of cellular enzymes, antagonism the acute and chronic nonspecific inflammatory reaction, suppress and the blocking-up virulence factor to histiocytic infringement, the reaction of elimination local inflammation finally plays a role by energy coupling.Do not find toxic and side effects, the reliable cure rate height of curative effect through the clinical practice test.Spinal column and extremities joint inflammation had significant curative effect.
Be the clinical trial structure of product of the present invention below:
1, treatment scapulohumeral periarthritis
This group is totally 43 examples, wherein male 26 examples, women 17 examples; Age 38-64 year, account for 80% more than 50 years old; Medical history 1-3 month; Case is one-sided.With the capable biceps brachii m. stndon sheath of product of the present invention, triceps muscle and supraspinatus synovial bursa, each infiltration injecting 2ml of triangular muscle synovial bursa.Through three infiltration injecting treatments, injected once in average 5 days, 37 examples of fully recovering, effective 6 examples, the shoulder joint edema is obviously improved, and does not see invalid case, and observing had 2 example recurrences in 1 year.
2, sacroiliac joint bursitis
This group is totally 25 examples, wherein male 16 examples, women 9 examples; Age 32-58 year; Medical history 1-2 month, do not have obvious inducement and account for 80%, what trauma history was arranged accounts for 20%.Reach injection 2ml behind the sclerotin, Ipsilateral sacroiliac joint synovial bursa each injection 3ml up and down with the capable waist 4-5 of product of the present invention Ipsilateral transverse process flesh starting point, needle point.Fully recover 19 examples, effective 6 examples are on average injected 3 times, and per 5 days once, and 4 examples are answered the seasonal variations recurrence.
3, gonarthromeningitis
This group is totally 44 examples, wherein male 27 examples, women 17 examples; Age 32-76 year, medical history 2-3 week.With the capable knee joint suprapatellar bursa of medicine of the present invention injectable drug 5ml, injected once in per 5 days, average 3 times, 36 examples of fully recovering, produce effects 4 examples, clinical symptom remission 3 examples, invalid 1 example is observed 2 example recurrences with examining.
4, the palm refers to and refers to a rheumatoid arthritis
This group is totally 7 examples, wherein male 3 examples, women 4 examples, and age 24-40 year, medical history 3-6, case is both hands and refers to more.With the capable metacarpophalangeal joints of getting involved of product of the present invention and each injection 1ml of interphalangeal joint chamber, be administered once average 2 times in per 5 days.5 examples of fully recovering, produce effects 2 examples are followed up a case by regular visits to and are recurred 2 examples half a year.
(4) specific embodiment
For a more detailed description to the present invention for example below in conjunction with accompanying drawing:
Ratio according to Energy mixture 90-100 unit, complex bone peptide 70-80mg, gentamycin 7.5-8 ten thousand units and 2% lignocaine 5-6mg is made mixture with each raw material mix homogeneously.Its best proportioning is Energy mixture 100 units, complex bone peptide 75mg, gentamycin 80,000 units, 2% lignocaine 5mg.Wherein said Energy mixture is the mixture of adenosine triphosphate, coenzyme A and inosine, and its mixed proportion is generally 1: 1: 1.
Get 1 in every mixture mixture that contains Energy mixture 100 units, complex bone peptide 75mg, gentamycin 80,000 units, 2% lignocaine 5mg, row 3 the injections of synovial bursa around articular cavity and the joint of getting involved, average injection every day is once injected three times altogether.
Claims (2)
1. medicine that soaks into treatment of arthritis, it is characterized in that: it is the resulting mixture of mixed according to Energy mixture 90-100 unit, complex bone peptide 70-80mg, gentamycin 7.5-8 ten thousand units and 2% lignocaine 5-6mg, and described Energy mixture is adenosine triphosphate, coenzyme A and 1: 1: 1 mixture of inosine.
2. the medicine of infiltration treatment of arthritis according to claim 1, it is characterized in that: it is the mixture of Energy mixture 100 units, complex bone peptide 75mg, gentamycin 80,000 units, 2% lignocaine 5mg, and described Energy mixture is adenosine triphosphate, coenzyme A and 1: 1: 1 mixture of inosine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100102301A CN100417415C (en) | 2006-06-28 | 2006-06-28 | Soakage of medication for treating arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100102301A CN100417415C (en) | 2006-06-28 | 2006-06-28 | Soakage of medication for treating arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1872339A CN1872339A (en) | 2006-12-06 |
| CN100417415C true CN100417415C (en) | 2008-09-10 |
Family
ID=37483047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100102301A Expired - Fee Related CN100417415C (en) | 2006-06-28 | 2006-06-28 | Soakage of medication for treating arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100417415C (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046253A1 (en) * | 1997-04-15 | 1998-10-22 | Astra Aktiebolag (Publ) | Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis |
| WO2003041724A1 (en) * | 2001-11-13 | 2003-05-22 | Alcon, Inc. | Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis |
| WO2005002611A1 (en) * | 2003-06-27 | 2005-01-13 | Indena S.P.A. | Formulations for the treatment of arhritis conditions |
| CN1569218A (en) * | 2004-01-12 | 2005-01-26 | 江勇 | Bone peptide for injection and its preparation method |
| CN1579541A (en) * | 2004-02-23 | 2005-02-16 | 江卫世 | Compound bone peptide for injection and its preparation process |
| CN1679609A (en) * | 2005-02-03 | 2005-10-12 | 北京阜康仁生物制药科技有限公司 | Compound energy mistura fat-soluble vitamins adult preparation and use thereof |
-
2006
- 2006-06-28 CN CNB2006100102301A patent/CN100417415C/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046253A1 (en) * | 1997-04-15 | 1998-10-22 | Astra Aktiebolag (Publ) | Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis |
| WO2003041724A1 (en) * | 2001-11-13 | 2003-05-22 | Alcon, Inc. | Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis |
| WO2005002611A1 (en) * | 2003-06-27 | 2005-01-13 | Indena S.P.A. | Formulations for the treatment of arhritis conditions |
| CN1569218A (en) * | 2004-01-12 | 2005-01-26 | 江勇 | Bone peptide for injection and its preparation method |
| CN1579541A (en) * | 2004-02-23 | 2005-02-16 | 江卫世 | Compound bone peptide for injection and its preparation process |
| CN1679609A (en) * | 2005-02-03 | 2005-10-12 | 北京阜康仁生物制药科技有限公司 | Compound energy mistura fat-soluble vitamins adult preparation and use thereof |
Non-Patent Citations (2)
| Title |
|---|
| 降钙素与复方骨肽联合治疗骨质疏松症的临床观察. 黄剑锋等.贵阳医学院学报，第30卷第4期. 2005 |
| 降钙素与复方骨肽联合治疗骨质疏松症的临床观察. 黄剑锋等.贵阳医学院学报，第30卷第4期. 2005 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1872339A (en) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Edwards et al. | Autologous blood injections for refractory lateral epicondylitis | |
| CN100534487C (en) | Medicine for treating osteoarthrosis caused by wind, cold and damp and preparation method thereof | |
| CN100500201C (en) | Chinese herbal medicine for treating prostatitis | |
| CN102198091B (en) | Acupuncture point injection | |
| CN101664491A (en) | Medicament for treating arthralgia-synadrome and preparation method thereof | |
| US20150359860A1 (en) | Method of treating fibrosis in skeletal muscle tissue | |
| CN103393714A (en) | Local anesthesia pain-relieving time-delay agent | |
| CN100417415C (en) | Soakage of medication for treating arthritis | |
| CN104173373A (en) | Pharmaceutical composition for treating chronic pain and application of drug composition | |
| CN103054965B (en) | External analgesic plaster for treating arthralgia and preparation method of external analgesic plaster | |
| CN102805847B (en) | Medicine for treating arthralgia | |
| CN102406898B (en) | Drug for treating psoriasis vulgaris, and preparation method thereof | |
| Gong et al. | Curative effect of medicine cake sticking ultrasound drug penetration combined with body training on hemiplegia after stroke: An in vitro ultrasound targeted drug controlled release technology | |
| CN100544761C (en) | A kind of medicine for the treatment of coronary heart disease | |
| CN103494861A (en) | Traditional Chinese medicine moxibustion therapy patch for treating arthromyodynia | |
| CN104771469A (en) | External traditional Chinese medicine for treating ankle soft tissue injury | |
| CN104606324A (en) | Traditional Chinese medicine compound pain resisting medicine and preparation method thereof | |
| CN103417913B (en) | A kind of Chinese medicinal ointment for the treatment of prolapse of lumbar intervertebral disc and preparation method thereof | |
| CN105106338A (en) | Medical wine for treating rheumatoid arthritis | |
| CN111481655B (en) | External fumigation-washing traditional Chinese medicine composition for treating post-stroke myotonia increase | |
| CN100409877C (en) | Chinese medicine preparation for treating hyperosteogeny | |
| Tao et al. | Clinical study on treatment of shoulder periarthritis with electro-acupuncture on point Jianyu (LI 15) | |
| Shen et al. | Effects of Probiotics Combined with Traditional Chinese Medicine, Acupressure Massage, and Acupuncture Point Application on Constipation. | |
| RU2344823C2 (en) | Method of arthrosis deformans or polyarticular rheumatoid arthritis treatment | |
| Yuqiu et al. | Pain and promote healing soup with microwave therapy to promote hemorrhoids clinical observation of postoperative wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080910 Termination date: 20110628 |